Chemistry:ATC code L
From HandWiki
ATC code L Antineoplastic and immunomodulating agents is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL.[4]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.Template:ATC code L
References
- ↑ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/ATC/index.html. Retrieved 2020-02-01.
- ↑ "ATC-Klassifikation mit definierten Tagesdosen DDD". German Institute for Medical Documentation and Information. https://www.dimdi.de/dynamic/de/arzneimittel/atc-klassifikation/. Retrieved 2020-02-01.
- ↑ "ATC/DDD Index 2020: code L". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/?code=L.
- ↑ "ATCvet Index 2020: code QL". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcvet/atcvet_index/?code=L.
| SPs/MIs (M phase) |
| ||||||
|---|---|---|---|---|---|---|---|
| DNA replication inhibitor | |||||||
| Photosensitizers/PDT | |||||||
| Other |
| ||||||
| |||||||
| CI monoclonal antibodies ("-mab") |
| ||||||
|---|---|---|---|---|---|---|---|
| Tyrosine kinase inhibitors ("-nib") |
| ||||||
| Other |
| ||||||
| Endogenous |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exogenous | |||||||||||||
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
 | 0.00  (0 votes) |
